Thus, interest has been raised for the use of drugs targeting the sEH for the treatment of myocardial infarction [12], atherosclerosis [13], ischemia [14], inflammation-related pathologies [15] and metabolic syndrome [16], and hypertension [17]. Here, EPHX2 is linked to hypertensive disorder.